The three giants dominate the $90 billion market, and the dominant position is firmly established

Recently, there has been a lot of news about drugs in the field of diabetes
.
On March 29, Novo Nordisk's high-dose Ozempic (semaglutide) 2mg injection was approved by the US FDA for marketing
.
On March 14, Eli Lilly's long-acting insulin LY3209590 injection clinical trial application was accepted
.
Whether globally or domestically, the diabetes drug market has always been led by three multinational giants, Novo Nordisk, Eli Lilly and Sanofi
.
Looking at insulin and its analogs alone, the industry concentration is higher.
In 2021, the sales of 11 major products of the three giants will exceed 11.
7 billion US dollars.
After the centralized procurement of insulin in the Chinese market, the pressure of multinational pharmaceutical companies will not decrease
.
GLP-1 receptor agonists have emerged in recent years, and semaglutide sales have increased by 30 times in just 4 years, and dulaglutide will struggle to hold the top position with sales of US$6.
472 billion in 2021
.
The three giants have grabbed the $90 billion market, and Novo Nordisk has firmly maintained the "world's first brother" Recently, there have been constant news about drugs in the field of diabetes
.
On March 29, Novo Nordisk announced that the U.
S.
FDA has approved Ozempic (semaglutide) 2mg injection
.
Ozempic is a GLP-1 analog for the treatment of type 2 diabetes.
Ozempic has previously been approved for 0.
5mg and 1mg therapeutic doses
.
On March 14, the CDE official website showed that Eli Lilly's long-acting insulin LY3209590 injection clinical trial application was accepted
.
According to statistics, the global diabetes drug market will exceed US$90 billion in 2022.
Whether globally or domestically, the diabetes drug market has always been led by three multinational giants, Novo Nordisk, Eli Lilly and Sanofi
.
Novo Nordisk focuses on the research and development of diabetes and obesity drugs, and has occupied the dominant position in the field of diabetes for many years
.
In 2021, Novo Nordisk's diabetes business revenue will reach US$17.
996 billion (DKK 113.
197 billion), accounting for 80% of the company's total revenue, maintaining its position as the "global leader" in the field of diabetes
.
Among them, revenue from insulin was USD 8.
904 billion (DKK 56.
006 billion), revenue from GLP-1 drugs was USD 8.
521 billion (DKK 53.
597 billion), and revenue from other drugs was USD 571 million (DKK 3.
594 billion)
.
At the recent capital market day event, Novo Nordisk revealed that the company's goal in the field of diabetes is to strengthen its leadership in commercialization and seize one-third of the global market share
.
Novo Nordisk's diabetes business revenue in 2021 (unit: million DKK) Lilly, which has long been competing with Novo Nordisk for the leading position, is still struggling to catch up
.
In 2021, Eli Lilly's diabetes business revenue will be $13.
188 billion, accounting for 47% of the company's total revenue, ranking second in the global diabetes field
.
In the past three years, Lilly's diabetes business revenue has shown a slight decline in the proportion of the company's total revenue, and the proportion in 2021 will drop by 3% compared with 2019
.
Lilly's total revenue distribution in the past three years (unit: US$100 million) Sanofi's diabetes drug pipeline is weaker than that of Novo Nordisk and Eli Lilly, with only three major diabetes products
.
Insulin glargine (Lantus) is Sanofi's heaviest insulin drug, and it is also the insulin drug that can compete with Novo Nordisk and Eli Lilly
.
Sales of Sanofi's Lantus soared after its launch in 2000, reaching a peak of $7.
6 billion (€6.
390 billion) in 2015, but sales began to fall rapidly with the launch of Eli Lilly's insulin glargine analog , sales in 2021 will only be 2.
96 billion US dollars (2.
494 billion euros)
.
Sanofi's diabetes business revenue in 2021 (unit: million euros) In China, the diabetes drug market is currently dominated by multinational pharmaceutical companies, with Novo Nordisk, Eli Lilly and Sanofi occupying the TOP3 position
.
According to the terminal data of China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions), in the first half of 2021, Novo Nordisk's market share in diabetes drugs is close to 30%, which is worthy of the name.
Overlord
.
Sanofi came in second with insulin glargine (Lantus) with a market share of 8.
33%
.
Eli Lilly's diabetes drug market share is 6.
27%, ranking third
.
11 best-selling products dominate the screen, centralized procurement and pressure do not reduce Insulin and its analogs are important types of drugs for the treatment of diabetic patients.
According to the data released by Novo Nordisk, the market share of insulin and its analogs accounts for 40% of the global diabetes drugs.
% or so
.
Globally, the industry of insulin and its analogs is highly concentrated, with Novo Nordisk, Eli Lilly and Sanofi leading the way.
In 2021, the sales of 11 best-selling products of the three giants will total $11.
765 billion
.
Novo Nordisk has a rich pipeline of insulin and its analogs, and has a layout of second-generation, third-generation, and fourth-generation insulins
.
In 2021, rapid-acting insulin aspart (NovoRapid/NovoLog) has the best revenue, with revenue reaching $2.
534 billion
.
Recombinant insulin lispro (Humalog) is the leading product among Eli Lilly and its analogues, with fast onset of action and shorter duration of action, with global sales of $2.
453 billion in 2021
.
Sanofi's layout in insulin and its analogs is more inclined to be less and more refined.
The third-generation insulin insulin glargine (Lantus) is young, with sales of US$2.
96 billion in 2021, surpassing Novo Nordisk's fast-acting insulin aspart.
(NovoRapid/NovoLog)
.
In terms of growth rate, due to the impact of the current new hypoglycemic drugs and the fierce competition between drugs, except for Novo Nordisk's Ryzodeg, Fiasp, Tresiba, the growth rate of the rest of the three giants' insulin and analogs has slowed down.
of products even experienced a decline in growth rate
.
In 2022, the major insulin products of the three giants will continue to exert pressure on the performance of Novo Nordisk, Eli Lilly and Sanofi in insulin and their analogues, mainly due to the price drop brought about by the centralized procurement of insulin in the Chinese market
.
In May this year, the sixth batch of national centralized insulin procurement projects will be officially implemented.
In the previous bidding, domestic and foreign pharmaceutical companies actively participated in the battle, and a total of 42 products from 11 pharmaceutical companies were selected
.
Multinational pharmaceutical companies changed their cold attitude in the centralized procurement of chemical drugs, and 4 multinational pharmaceutical companies including Novo Nordisk, Eli Lilly, Sanofi and BIOTON selected 17 products
.
Judging from the price reduction of this centralized procurement, Novo Nordisk has cut prices by about 46%, Eli Lilly about 10%, and Sanofi about 8%
.
According to the terminal data of Chinese public medical institutions on Minet.
com, Novo Nordisk alone occupies about 46% of the market share in the domestic insulin and its analogues market.
Sanofi accounts for about 15%, Lilly accounts for about 11%, the three multinational giants together account for more than 70% of the market share, and the remaining domestic pharmaceutical companies can only share less than 30% of the remaining market
.
However, after the implementation of the sixth batch of national centralized insulin procurement projects, the pattern of domestic insulin and its analogs may change.
Under the active attack of domestic pharmaceutical companies such as Gan & Lee Pharmaceuticals, the market share of domestic companies is expected to further expand.
It is inevitable that market share will be grabbed
.
The Chinese market is Novo Nordisk's second largest market in the world.
In the recent Capital Markets Day event, Novo Nordisk once again mentioned that "China remains a key strategic opportunity"
.
After the implementation of centralized procurement, the price reduction of Novo Nordisk insulin will definitely have an impact on the company's global revenue and growth rate in 2022.
The reallocation of resources to find new growth points is an important consideration for the company at present
.
And Eli Lilly and Sanofi have achieved "price-for-volume", which may maintain or even boost the sales of insulin and its analogs, which were not growing at a high rate.

.
Two "blockbusters" have soared sales, and oligarchic competition continues Unlike insulin and its analogs, the GLP-1 receptor agonist market has sprung up in recent years, and has become the main driving force for the growth of the global diabetes drug market
.
At present, 8 GLP-1 drugs have been approved for marketing in the world, including AstraZeneca's Exenatide, GlaxoSmithKline's Albiglutide, Renhui Bio's Benaglutide, Jiangsu Hao Sen's macrogolloxenatide, Sanofi's Lixisenatide, Novo Nordisk's Liraglutide and Semaglutide, and Eli Lilly's dulaglutide Glycopeptide (Dulaglutide)
.
In front of the long-acting GLP-1 drugs of Novo Nordisk and Eli Lilly, Sanofi's short-acting drug lixisenatide has been thrown out a few streets.
The GLP-1 drug market is mainly Novo Nordisk, Eli Lilly and so on.
Come to the battle between the two oligarchs
.
After Lilly's dulaglutide was launched in 2014, it became the strongest GLP-1 drug, successfully surpassing Novo Nordisk's liraglutide
.
But Novo Nordisk is not to be outdone.
Its blockbuster drug semaglutide injection was successfully launched in 2017, and it is also known as "the best diabetes drug in the world".
In 2019, Novo Nordisk also successfully developed oral semaglutide injection.
Glutide
.
In 2021, the global sales of Eli Lilly's dulaglutide will be US$6.
472 billion, and the total global sales of Novo Nordisk's semaglutide (including injection and oral) will reach US$6.
128 billion, with Eli Lilly temporarily leading
.
In terms of growth rate, semaglutide has maintained rapid growth in the four years since its launch
.
The gap between these two blockbuster drugs in 2021 is only US$300 million.
If there is no accident, semaglutide will surpass dulaglutide and become the sales champion of the new generation of GLP-1 drugs in 2022
.
Global sales of dulaglutide and semaglutide (unit: US$100 million) Novo Nordisk and Eli Lilly's competition in GLP-1 drugs is far from over
.
Novo Nordisk has a series of development plans for semaglutide, multi-indication expansion and multi-dose studies
.
At present, the research of semaglutide for peripheral arterial disease, diabetic retinopathy, chronic kidney disease and other indications is in clinical phase III, and oral semaglutide 25mg and 50mg dosage products are also in clinical phase III
.
Novo Nordisk's diabetes drug development pipeline In response to Novo Nordisk's strong offensive, Lilly focused on developing the GLP-R/GIPR dual-target agonist Tirzepatide to counter it
.
Currently, Tirzepatide is being developed for the treatment of type 2 diabetes and obesity.
According to clinical trial data, Tirzepatide's hypoglycemic and weight loss effect is better than semaglutide
.
Eli Lilly has submitted a new drug application for Tirzepatide to the US FDA in October last year for the treatment of type 2 diabetes
.
A successful launch of Tirzepatide would be another trump card for Eli Lilly, which is forecast to generate nearly $5 billion in sales in 2026
.
Tirzepatide's global R&D status Data source: official website of the company, Minet database If there are any omissions, please correct me!